Varenicline Versus Cytisine for Smoking Cessation in a Primary Care Setting: A Randomized Controlled Trial

Introduction

The European Union and Central Europe, in particular, has one of the highest proportions of deaths attributable to tobacco use. WHO has estimated that tobacco use is currently responsible for 16% of all deaths in adults over 30 years of age in this region^4. Croatia and Slovenia, countries in Central Europe, have a high prevalence of smoking due in part to, 1) cultural habits and a tradition of smoking tobacco; 2) problems with financing health care insurance systems, and 3) the strong influence of the tobacco industries on government policies. During the past two decades, Croatian and Slovenian tobacco control policies followed the strategies set forth by WHO; however, the impact on the prevalence of smoking differed between the countries^7,8 what might be attributable to the gap between the knowledge and current practices¹⁹ of tobacco control, health promotion and best practices in tobacco related disease prevention programs^21,21 although numerous research project²², interventional studies^23,24 and internationally recognized health promotion projects²⁵ to prevent and control tobacco use and smoking have been implemented in Croatia.

These are the additional reasons why our study aims to assess awareness of and interest in use of pharmacotherapy for smoking cessation and implement a smoking cessation program using pharmacotherapy in a real life setting — primary care practices in Croatia and Slovenia — and to investigate whether cytisine is at least as feasible and effective as Varenicline in helping smokers to quit in a randomized non-inferiority trial.

Prior to starting the treatment, all study subjects, regardless of group assignment, will fill out the Fagerström test for nicotine dependence. Patients will be given medication, explained how it is taken, and a phone number to call with any questions. General medicine doctors, specialized in family medicine and involved in the study are trained in the use of both Varenicline and cytisine, in recognising adverse events and in managing them (eg nausea, insomnia, nausea, and abnormal dreams, constipation, dyspepsia, sleep disorder, vomiting, and flatulence) and in providing behavioural support in a standardised manner. The MDs participating in the study will enter observations including any adverse events at every checkpoint in the study into a log for each participant. The participants will also fill in their observations and record their satisfaction with the treatment at the checkpoints.

The medication treatment with Varenicline will be given by standard medical protocol: we will start Varenicline treatment one week prior to the patient’s target quit date at 0.5 mg once daily and increase it to 0.5 mg twice daily on day 4. On the target quit date (day 8), the dose will be increased to 1 mg twice daily and maintained for 12 weeks ^32.

Patients assigned to Cytisine will be given a 25 days supply by standard medical protocol and asked to reduce their smoking during the first 4 days of treatment with and aim to quit on the 5^th day. We will follow the standard manufacturer’s dosing protocol:³² days 1 through 3, one tablet every 2 hours through the waking day (up to six tablets per day); days 4 through 12, one tablet every 2.5 hours (up to five tablets per day); days 13 through 16, one tablet every 3 hours (up to four tablets per day); days 17 through 20, one tablet every 4 to 5 hours (three tablets per day); and days 21 through 25, one tablet every 6 hours (two tablets per day).

During the treatment period, all patients in the study regardless of assignment to Varenicline or cytisine groups will receive weekly calls from a research assistant for the first 5 weeks, then every two weeks for a total of 12 weeks. The RA will inquire about medication adherence and smoking status using the Fagerström test for nicotine dependence, motivate the patient to continue taking medications, encourage them to stop smoking, and ask about possible side effects or other issues. We will hire six RAs for practices in Slovenia and six for practices in Croatia. They will receive clinical research training particularly related to our study, and brief training in smoking cessation counseling. Prior to study start, we will develop a smoking cessation program manual specifying all RA interventions including language to use while talking with patients and how to document the interventions for future analyses.

Patients will be given medication, explained how it is taken, and a phone number to call with any questions. Inclusion criteria for the study: 1) having a primary care physician at one of the 24 primary care practices in Croatia or at one of 19 primary care practices in Slovenia during this study; 2) aged 18 or older; 3) indicate a desire to quit smoking via survey; 4) do not have contraindications to the use of the medicines being tested (according to the summary of product characteristics for Varenicline and cytisine); 5) indicate an interest in pharmacotherapy via survey. Exclusion criteria for the study: 1) persons with cognitive impairment; 2) with a mental disorder, whether treated or not; 3) judged by the field investigators to have insufficient collaboration/adherence in treatment to participate in the trial; 4) considered by field investigators to have frequent adverse reactions to multiple drugs in the previous treatment of acute and chronic diseases; 5) women who are pregnant or breastfeeding.

Methods

Discussion

In a context of patients’ “normal” health behavior patterns, the primary care practices would be an ideal real-life setting for the implementation and evaluation of pharmacotherapy for smoking cessation. They are the setting where participants would normally receive treatment from their medical care providers. However, providing smoking cessation therapy with cytisine and Varenicline to primary care patients in the time of the COVID-19 pandemic was a particular challenge. Almost all GP specialists participating in the study noticed, observed and came to the conclusion that COVID-19 pandemic has made an important impact on behavior of patients and primary care physicians that, although significant, is hard to quantify and measure.

The possible positive motivation of the study participants to stop smoking might be related to the potential heightened awareness that tobacco use may increase the risk of suffering from serious symptoms due to COVID-19. Early research indicated that, compared to non-smokers, having a history of smoking may substantially increase the chance of adverse health outcomes for COVID-19 patients, including being admitted to intensive care, requiring mechanical ventilation and suffering severe health consequences ^{29, 30}. Studies and evidence from China also show that people who have cardiovascular and respiratory conditions caused by tobacco use are at higher risk of developing severe COVID-19 symptoms. ³¹

The possible negative effect might be connected to the fact that during the critical period of the study (September-December 2020 and March-May 2021), after recruitment was completed and the Fagestrom test administered, patients and primary care physicians in both Slovenia and Croatia were living under “lockdown” while facing the threat reflected in two of the globally fastest growing numbers of confirmed COVID-19-related deaths per million (Figure 1). The physicians were occupied with COVID-19 patients and patients were living under stress, and were reluctant to take a risk of leaving their homes and visiting GP’s offices.

• Download figure
• Open in new tab

Figure 1.

Growth of COVID-19 deaths per million in Croatia and Slovenia in the period of the clinical trial (August-December) as compared to the same period in the USA and the UK

Recruitment started on 14 July 2020, with results expected to be available in September 2021.

Clinical Trial Registration

Trial Registration number: KL:530-07/18-01/72 UB: 381-15/60-18-04

Study limitations

Smoking status as documented in the practices’ registries may not be up to date, so the number of current smokers could be different than stated in our proposal. We used conservative estimates and believe that we can achieve our recruitment goal. However, we will closely monitor recruitment per practice/country and if lower than anticipated, we will add one practice in Slovenia and one in Croatia to achieve our recruitment target of 380 patients interested in pharmacotherapy for smoking cessation.

Smoking status will be self-reported

The family medicine practices participating in this study have first class clinicians and staff. They are located in large cities and affiliated with academic medical centers so results might not be generalizable to community/rural family medicine practices.

Funding

This trial is funded by a 3-year project grant from the GRAND FUNDATION, Gobal Research Awards for Nicotine Dependance - An independently-reviewed competitive grants program supported by Pfizer. Pfizer project reference number WI231434.

Declaration of interests

The project have received smoking cessation medication and matching placebo from Pfizer (under their investigator-initiated research program, 2017). The cytisine (Tabex®) ³² was purchased for the trial using the project funding and Varenicline (Champix®), ³³manufactured by Pfizer was obtained free of charge from the Pfizer). Pfizer was not and will not be involved in the design, conduct or analysis of the trial.

Ethical considerations

Trial participants are not seen and receive no reimbursement for their time (although trial medication is free). A two-step verbal consent process is used. Ethics approval was obtained on 13 December 2018 from the National Ethical Committee of the Republic of Croatia. Agency for Medical Products and Medical Devices of Republica of Slovenia ethics approval was obtained on 16 Octobber 2019 following the guidelines of the European Medical Agency and Committee for proprietary Medicinal Products: “Note for Guidance On Good Clinical Practice” CPMP/ICH/135/95)